MASH — my 24-week log, condensed into one table
MASH — my 24-week log, condensed into one table, which sounds obvious until you try to state the evidence for it. It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is…
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
Removed the escalation schedule. Unapproved compound, no protocols for other members, no exceptions.
Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.
do not import intuitions from the obesity programmes
What does the tolerability table say at that dose?
Are you reading the publication or a summary?
How fast was the escalation in that protocol?